- Gitelman, Stephen;
- Greenbaum, CJ;
- Beam, CA;
- Boulware, D;
- Gitelman, SE;
- Gottlieb, PA;
- Herold, KC;
- Lachin, JM;
- McGee, P;
- Palmer, JP;
- Pescovitz, MD
Interpretation of clinical trials to alter the decline in β-cell function after diagnosis of type 1 diabetes depends on a robust understanding of the natural history of disease. Combining data from the Type 1 Diabetes TrialNet studies, we describe the natu